“The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's top five oncology players by 2035.
Original story
Continue reading at Japan Times Latest
www.japantimes.co.jp
Summary generated from the RSS feed of Japan Times Latest. All article rights belong to the original publisher. Click through to read the full piece on www.japantimes.co.jp.